Controlled-Release CNP Agonist for Achondroplasia Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for achondroplasia, such as BMN-111, have a short half-life and require frequent administration, leading to cardiovascular adverse effects when doses are increased to maintain efficacious drug levels.
Innovation Solution
Development of a controlled-release CNP agonist with an at least 5-fold longer degradation half-life in an in vitro NEP degradation assay, allowing for efficient protection against NEP degradation and enabling subcutaneous administration without the need for continuous infusion.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If the dose of CNP agonist is increased to maintain efficacious drug levels, then the therapeutic effect is improved, but cardiovascular adverse effects increase
Solution Approach 1:
The patent employs controlled-release technology to deliver CNP agonist in periodic pulses rather than continuous high-dose administration. The formulation releases the drug at controlled intervals, maintaining therapeutic levels while allowing drug-free periods that reduce cumulative cardiovascular stress and adverse effects
Solution Approach 2:
The controlled-release formulation is designed to maintain steady therapeutic levels of CNP agonist in advance, preventing the need for high peak doses. By establishing sustained release kinetics beforehand, the system avoids the cardiovascular stress associated with bolus dosing while ensuring therapeutic efficacy is achieved and maintained
2Ease of operation
If CNP is administered via subcutaneous route, then ease of administration is improved, but degradation by NEP and removal by NPR-C reduces bioavailability
Solution Approach 1:
The patent uses a controlled-release formulation as an intermediary system that protects CNP agonist from premature degradation by NEP and NPR-C in subcutaneous tissue. The formulation matrix acts as a protective barrier, releasing the drug in a controlled manner that bypasses the rapid clearance mechanisms present in subcutaneous space
Solution Approach 2:
The invention modifies the physical and chemical parameters of CNP agonist delivery by incorporating it into a controlled-release matrix. This changes the release kinetics and protects the peptide from enzymatic degradation, enabling subcutaneous administration to achieve sufficient bioavailability despite the presence of degrading enzymes and clearance receptors
3Stability of the object's composition
If PEG is added to CNP to increase resistance to NEP cleavage, then stability against degradation is improved, but CNP functional activity decreases
Solution Approach 1:
Instead of directly conjugating PEG to CNP, the patent uses a controlled-release formulation as an intermediary approach. The formulation provides physical protection and controlled release without covalent modification of the CNP molecule, thereby maintaining full biological activity while achieving stability against NEP degradation through the matrix barrier
4Reliability
If CNP agonist is administered via continuous intravenous infusion, then therapeutic effect is maintained, but complexity of administration and risk of adverse effects increase
Solution Approach 1:
The controlled-release formulation is designed to self-regulate drug release kinetics without requiring external control systems. Once administered, the formulation automatically maintains therapeutic levels through its built-in release mechanism, eliminating the need for continuous infusion pumps, monitoring systems, and specialized administration infrastructure
Solution Approach 2:
The formulation delivers CNP agonist in controlled periodic releases rather than requiring continuous infusion. This converts a complex continuous administration regimen into a simpler intermittent release system that maintains therapeutic efficacy while reducing administrative complexity and associated risks
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The controlled-release CNP agonist provides sustained exposure to efficacious drug levels, reducing the frequency of administration and minimizing cardiovascular side effects, while maintaining full activity and access to the growth plate.
Implementation Method 1
controlled-release CNP agonist having an at least 5-fold longer degradation half-life in an in vitro NEP degradation assay than the corresponding released CNP agonist
Data Source
AI summary
The present invention relates to controlled-release CNP agonists having an at least 5-fold longer degradation half-life in an in vitro NEP degradation assay than the corresponding released CNP agonist, to pharmaceutical compositions comprising said controlled-release CNP agonist, their use and to methods of treatment.